Alnylam Pharmaceuticals
ALNY
ALNY
282 hedge funds and large institutions have $11.7B invested in Alnylam Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 102 increasing their positions, 65 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
282
Holders Change
+47
Holders Change %
+20%
% of All Funds
6.4%
Holding in Top 10
14
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+16.67%
% of All Funds
0.32%
New
76
Increased
102
Reduced
65
Closed
28
Calls
$165M
Puts
$144M
Net Calls
+$20.6M
Net Calls Change
-$48.6M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$1.55B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
$1.89B |
| 3 |
BlackRock
New York
|
$904M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
$923M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
$65.6M |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
$1.17B |
| 2 |
Dodge & Cox
San Francisco,
California
|
$1.05B |
| 3 |
D.E. Shaw & Co
New York
|
$34.6M |
| 4 |
Goldman Sachs
New York
|
$151M |
| 5 |
PA
Perceptive Advisors
New York
|
$169M |
